Barentz strengthens Indian platform with acquisition of Anshul Life Sciences

Hoofddorp, The Netherlands, July 31, 2024. - Barentz International, a leading global specialty ingredients solution provider, announces the acquisition of Anshul Life Sciences Group (“Anshul Life Sciences”) in India, a high-end life science focused specialty chemicals distributor that caters to regulated Pharmaceuticals, Food & Nutraceuticals and Personal Care markets. With this strategic move Barentz establishes a leading life science distribution platform in India and reinforces its commitment to providing innovative solutions, technical expertise, and an even more innovative range of ingredients to customers and principals pan-India.

The acquisition emphasizes Barentz' commitment to the Indian market and is expected to open a realm of strategic opportunities for growth across the country and the broader Asia Pacific region. Both companies are committed to ensuring a seamless transition and maintaining the highest standards of value-added services.

Highlights:

• The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform.
• Anshul Life Sciences enforces and complements Barentz India pharmaceuticals ingredients portfolio with high-quality excipient, APIs and intermediates and widens our Personal Care and Nutraceuticals offering.
• The combination will unlock significant growth potential across Asia Pacific.
• Nagarajan Kailasam (CEO) and the current team of Anshul Life Sciences will continue to manage the day-to-day business operations.

Marc Duchene, CEO APAC: “We are extremely excited to welcome Anshul Life Sciences to the Barentz Group. The acquisition underpins our ambitions to further grow in India, one of our key strategic markets, and the Asia Pacific region in general. The acquisition benefits our customers and principals by providing access to a broader portfolio of high-quality pharmaceuticals excipients and products and a deeper pool of expertise. We are delighted that Mr. Nagarajan will continue to lead the business. Together, we aim to enhance our offering and better serve the needs of the dynamic Indian market and beyond.”

Nagarajan Kailasam, CEO of Anshul Life Sciences: “Barentz aligns strongly with the entrepreneurial spirit and ethical standards of Anshul Life Science’s founding partners. We are excited to join the Barentz family and start our collaboration to capture the enormous potential of the Indian market by offering even more comprehensive solutions to our customers and principals in the Indian market and beyond. We are looking forward to the future and the growing international reach that this strategic move will bring to Anshul Life Sciences.”